Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030
A detailed assessmentof the current market landscape, including information on drug developer(s),phase of development

To order this detailed 350+ page report, please visit this -


Key Inclusions

§ A detailed assessmentof the current market landscape, including information on drug developer(s),phase of development (marketed, clinical and preclinical / discovery stage) oflead candidates, target immune checkpoints, their respective mechanisms ofaction (inhibitory or stimulatory),  type of therapeutic modality used (monoclonalantibody, antibody fragment, small molecule and others), route ofadministration (intravenous, subcutaneous, oral and others), target diseaseindication, target therapeutic area and type of therapy (monotherapy,combination therapy and both). 

§ A detailed analysisof more than 590 completed, ongoing and planned clinical studies of nextgeneration immune checkpoint inhibitors and stimulators, highlighting prevalenttrends across various relevant parameters, such as current trial status, trialregistration year, phase of development, study design, leading industrysponsors / collaborators (in terms of number of trials conducted), trialfocus, type of target, target indication(s), target therapeutic area(s),enrolled patients population and regional distribution.

§ Detailed profiles ofdevelopers of next generation immune checkpoint modulators (shortlisted onthe basis of the number of pipeline products), featuring an overview of thecompany, its financial information (if available), a detailed descriptionof its product portfolio and recent collaborations. In addition, each profileincludes an informed future outlook.

§ An in-depth analysisof more than 490 grants that have been awarded to research institutes engagedin next generation immune checkpoint therapy-related projects, in the periodbetween 2016 and 2019 (till November), including analysis based onimportant parameters, such as year of grant award, amount awarded,administration institute center, funding institute center, support period, typeof grant application, purpose of grant award, grant mechanism, popular targetimmune checkpoints, responsible study section, focus area, prominent programofficers, and type of recipient organizations. It also features a detailedanalysis based on the types of target immune checkpoints and therapeutic areas,along with a multivariate grant attractiveness analysis based on parameters,such as grant amount, support period, type of grant application and number ofdisease indications under investigation.

§ An analysis of thepartnerships that have been established in the recent past, covering R&Dcollaborations, licensing agreements (specific to affiliated technologyplatforms and product candidates), product development and commercializationagreements, clinical trial agreements, manufacturing agreements, mergers andacquisitions, manufacturing and service agreements, and other relevant types ofdeals. 

§ An insightfulcompetitiveness analysis of biological targets, featuring a [A]three-dimensional bubble representation that highlights the targets that arebeing evaluated for next generation immune checkpoint therapy development,taking into consideration the number of lead molecules based on a particulartarget, phase of development of candidate therapies, number of grants andnumber of publications [B] a five-dimensional spider-web analysis, highlightingthe most popular immune checkpoint targets.

§ An analysis of thebig biopharma players engaged in this domain, featuring a heat map based onparameters, such as number of therapies under development, target diseaseindications, partnership activity and target portfolio.

§ Informed estimates ofthe existing market size and the future opportunity for next generation immunecheckpoint inhibitors and stimulators, over the next decade. Based on multipleparameters, such as disease prevalence, anticipated adoption of next generationcheckpoint modulator therapies and their likely selling price, we have providedinformed estimates on the evolution of the market for the period 2020-2030.


The report also features the likelydistribution of the current and forecasted opportunity across important marketsegments, mentioned below:

  • Target Disease Indication 

§ Breast Cancer

§ Chronic Lymphocytic Leukemia

§ Colorectal Cancer

§ Head and Neck Cancer

§ Lung Cancer

§ Lupus Nephritis

§ Melanoma

§ Multiple Myeloma

§ Primary Sjögren's Syndrome

§ Others 


  • Target Immune Checkpoint

§ B7-H3

§ CD38

§ CD40

§ CD47

§ Others


  • Mechanism of Action

§ Inhibitory

§ Stimulatory


  • Therapeutic Modality

§ Monoclonal Antibody

§ Small Molecule


  • Type of Therapy 

§ Monotherapy 

§ Combination Therapy


  • Route of Administration

§ Intravenous

§ Subcutaneous

§ Others


  • Key Geographical Regions 

§ North America

§ Europe

§ Asia-Pacific and the Rest of the World 


To request sample pages, please visit this -


Key Questions Answered

§ Who are the leadingindustry players engaged in the next generation immune checkpoint inhibitorsand stimulators market?

§ What are the mostimportant next generation immune checkpoint targets?

§ For which diseaseindications are next generation immune checkpoint therapies being developed?

§ What are the keyfactors that are likely to influence the evolution of this market?

§ What kind ofinitiatives have been undertaken by big pharma players engaged in this domain?

§ Which partnershipmodels are commonly adopted by stakeholders in this industry?

§ How is the currentand future market opportunity likely to be distributed across key marketsegments?


You may also be interested in the following titles:

1.    NeoantigenTargeted Therapies Market, 2019-2030

2.    BispecificAntibody Therapeutics Market (4th Edition), 2019-2030

3.    GlobalStem Cells Market: Focus on Clinical Therapies, 2020-2030


Contact Us

Gaurav Chaudhary

+1 (415) 800 3415